Jade Biosciences
JBIO
75 hedge funds and large institutions have $315M invested in Jade Biosciences in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 40 increasing their positions, 4 reducing their positions, and 30 closing their positions.
3,798.79% more ownership
Funds ownership: 3.12% → 3,801.92% (+3,799%)
900% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 4
296% more capital invested
Capital invested by funds: $79.6M → $315M (+$236M)
4% less funds holding
Funds holding: 78 → 75 (-3)
10% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 30
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.52M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$165M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$110M |
| 3 |
VA
VR Adviser
New York
|
+$110M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$85.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$4.52M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$3.67M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$3.62M |
| 4 |
AI
Allostery Investments
Stamford,
Connecticut
|
-$3.57M |
| 5 |
Blackstone Inc
New York
|
-$2.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CA
101
CoreCap Advisors
Southfield,
Michigan
| – | -$1.68K | -19 | Closed |
|
|
CCM
102
Coldstream Capital Management
Bellevue,
Washington
| – | -$262 | -3 | Closed |
|
|
AB
103
Amalgamated Bank
New York
| – | -$34 | -1 | -10% |
|
104
Osaic Holdings
Scottsdale,
Arizona
| – | -$30 | – | – |
|
|
TWD
105
True Wealth Design
Akron,
Ohio
| – | -$23 | – | – |
|
|
CAL
106
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$204 | +6 | New |
|
JBIO Hedge Fund Activity: Q2 2025 in Review
75 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q2 2025, worth a combined $315M — up 296% from $79.6M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of JBIO and 27 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 40 added.
The largest buyer was Fidelity Investments, adding an estimated $165M. The largest seller was Atlas Venture Life Science Advisors, exiting entirely with an estimated $4.52M sold.
- 75 institutional investors held Jade Biosciences (JBIO) as of Q2 2025, down from 78 in Q1 2025.
- Funds reported $315M of Jade Biosciences stock for Q2 2025, up 296% quarter-over-quarter.
- 27 funds opened new Jade Biosciences positions in Q2 2025 and 30 closed out, a net change of -3 holders.
- The largest Jade Biosciences buyer in Q2 2025 was Fidelity Investments, an estimated $165M added.
- The largest Jade Biosciences seller in Q2 2025 was Atlas Venture Life Science Advisors, an estimated $4.52M sold.
Based on aggregated 13F filings for Q2 2025.